Red Light Holland Announces New Filament Health PEX010 European Research Shipment
Rhea-AI Summary
Red Light Holland (OTCQB: TRUFF) announced that Filament Health has completed a shipment of its botanical psilocybin drug candidate PEX010 into the European Union, released via a European Qualified Person, to supply multiple independent investigator-led studies, including projects linked to Nantes University Hospital and Region Stockholm in collaboration with Karolinska Institutet.
According to Red Light Holland, Filament only supplies PEX010 and is not running these trials. PEX010 now supports over 80 academic and philanthropic studies worldwide, backed by a portfolio of 76 issued patents across 13 families acquired when Red Light Holland closed its Filament transaction on April 30, 2026.
Positive
- PEX010 EU shipment supports multiple independent investigator-led clinical studies
- PEX010 supplies more than 80 academic and philanthropic research studies worldwide
- Acquisition added 76 issued patents across 13 patent families on April 30, 2026
Negative
- None.
News Market Reaction – TRUFF
In the Jul 16 session, TRUFF gained 7.18%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.
The Company is pleased to update that Filament completed a shipment of PEX010 into the European Union, released through its European Qualified Person ("QP"), in support of multiple investigator-led studies, including studies associated with Nantes University Hospital and Region Stockholm in collaboration with Karolinska Institutet. Each supported study is sponsored and conducted independently of Filament, whose involvement is limited to the supply of PEX010.
"These continued shipments reflect growing demand for pharmaceutical grade, naturally derived psilocybin and reinforce the expanding role of Filament Health's PEX010 in supporting academic and clinical research, while continuing to strengthen the operational and quality systems that support reliable global supply," said Todd Shapiro, CEO & Director of Red Light/Filament Health.
PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. On April 30, 2026, Red Light Holland completed its previously announced acquisition of Filament Health Corp., including its portfolio of 76 issued patents across 13 patent families and its lead drug candidate, PEX010, creating a global leader in psychedelic drug development, commercialization, and distribution.
About Red Light Holland
Red Light Holland is an Ontario based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.
About Filament Health
Filament Health is a clinical stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.
For additional information on Red Light:
Todd Shapiro, Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlight.co
Website: www.RedLight.co
For additional information on Filament:
Todd Shapiro, Chief Executive Officer & Director
Website: www.filament.health
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its respective subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.
Examples of such information include statements with respect to: the agreement with the Jewish General Hospital and the anticipated supply of PEX010 thereunder; the completed shipment of PEX010 into the European Union and the anticipated supply of PEX010 to the referenced studies; the conduct and progress of the referenced studies, each of which is sponsored and conducted independently of Filament; the continued expansion of Filament's clinical research footprint in Canada, Europe and other jurisdictions; the expected demand for standardized, naturally derived psilocybin; the recently completed acquisition of Filament Health and the expected integration of Filament's clinical infrastructure and intellectual property; and the future development, commercialization, and regulatory approval of PEX010.
Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the continued ability of Filament to supply PEX010; the performance by the referenced institutions and the Company of their respective obligations under the applicable agreements; the continued progression of the referenced studies; the successful integration of Filament Health following the completed acquisition; the ability to obtain and maintain any required regulatory permits and approvals, including Qualified Person batch release and import and export authorizations; and general business, market and economic conditions.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, namely: regulatory or enforcement developments affecting the legal framework for psilocybin supply and research; the risk that integration of Filament Health is not completed as anticipated; the risk that anticipated supply under the referenced agreements does not materialize as expected; the risk that the referenced studies do not proceed or progress as anticipated; delays in regulatory permitting, including Qualified Person batch release and import and export authorizations; and adverse changes in the regulatory or political landscape affecting psychedelic research and access.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305430